Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Bicara Therapeutics Inc. submitted an initial beneficial ownership report for director Christy J. Oliger. The report lists no equity or derivative security transactions and does not list any current holdings or derivative positions. A remark references Exhibit 24, identified as a Power of Attorney.
Bicara Therapeutics Inc. reported that Kiran Mazumdar‑Shaw will resign from its Board and Nominating and Corporate Governance Committee effective July 28, 2026; her decision was stated not to result from any disagreement with the company. The Board appointed Jeremy Bender as a Class I director through the 2028 annual meeting and Christy Oliger as a Class II director through the 2029 meeting, effective the same date, and increased the authorized Board size from nine to ten directors.
Both new directors are deemed independent under Nasdaq rules and, as non‑employee directors, will receive compensation that includes an initial stock option award of 38,950 shares of common stock and cash fees under Bicara’s director compensation policy. Bender joins the Audit Committee, while Oliger and Carolyn Ng join the Nominating and Corporate Governance Committee. The Board also created a Launch Readiness Committee, including Bender, Oliger and chair Kate Haviland, to provide strategic and operational guidance on Bicara’s commercialization strategy and launch readiness for its lead program, ficerafusp alfa.
BlackRock, Inc. reported passive ownership of common stock of Bicara Therapeutics Inc. on a Schedule 13G. As of June 30, 2026, BlackRock beneficially owned 3,536,271 shares of Bicara common stock, representing 5.4% of the outstanding class.
BlackRock reported sole voting power over 3,464,981 shares and sole dispositive power over 3,536,271 shares, with no shared voting or dispositive power. Various underlying clients may receive dividends or sale proceeds, but no single client holds more than five percent of Bicara’s outstanding common shares.
Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar exercised options to acquire 10,000 shares of common stock at $3.7898 per share, then sold 10,000 shares in open-market transactions on July 10, 2026, pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026, and continues to hold shares directly.
Bicara Therapeutics Inc. director and President & COO Ryan Cohlhepp reported an exercise-and-sell transaction in company common stock. On July 8, 2026, he exercised stock options covering 18,750 shares of common stock at an exercise price of $3.7898 per share and received the underlying shares. On July 8–9, 2026, he executed open‑market sales totaling 28,750 shares at weighted average prices including $28.7589, $29.7961, $30.3549, and $29.00 per share. Following these transactions, he held 181,641 shares of common stock directly and 70,502 stock options directly. The sales were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on March 31, 2026.
Bicara Therapeutics Inc.'s Chief Financial Officer Ivan Hyep reported a set of July 8, 2026 equity transactions. He exercised stock options for 12,500 shares of common stock at an exercise price of $3.7898 per share and sold 28,000 common shares in open-market trades at weighted average prices between about $28.60 and $30.31. The sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2026.
BCAX insider Claire Mazumdar has notified of an intent to sell common stock under Rule 144. The plan covers 10,000 shares to be sold through UBS Financial Services on July 10, 2026, following a cash exercise of stock options. In the prior three months, Mazumdar sold 15,000 shares on April 20, 2026 for $354,145.50 and another 15,000 shares on May 18, 2026 for $300,577.50.
BCAX submitted a Form 144 reporting a proposed resale of 50,000 shares via a stock option exercise, listed as an issuer transaction to be effected for cash on 07/08/2026. The filing also records recent sales by David Raben: 50,000 shares on 06/25/2026 for $1,324,650.00, 5,500 shares on 05/26/2026 for $118,737.85, and 5,500 shares on 04/27/2026 for $125,830.01.
BCAX filed a Form 144 notice reporting the sale of 28,750 shares. The filing lists two planned or reported option exercises: 10,000 shares exercised on 05/12/2024 and 18,750 shares exercised on 07/08/2026. The filing also reports two sales during the past three months: 12,500 shares sold on 04/15/2026 for $287,591.25 and 12,500 shares sold on 05/15/2026 for $253,648.75.
BCAX affiliate submitted a Rule 144 notice reporting proposed and recent sales of Common Stock. The filing lists 28,000 shares and an aggregate dollar figure of $847,000.00 tied to the securities information. It also records two past sales of 9,200 shares each on 04/21/2026 and 05/21/2026 for $211,613.80 and $187,883.32, respectively.
The filing shows planned transfers linked to option exercises, including an entry of 12,500 shares associated with an exercise dated 07/08/2026 and 15,500 shares tied to an NQ exercise dated 05/08/2024. The record lists the broker as UBS Financial Services, Inc. and identifies NASDAQ as the market.